These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 4074435

  • 1. Hemodynamic effects of the antithrombotic drug cilostazol in chronic arterial occlusion in the extremities.
    Kamiya T, Sakaguchi S.
    Arzneimittelforschung; 1985; 35(7A):1201-3. PubMed ID: 4074435
    [Abstract] [Full Text] [Related]

  • 2. Hemodynamic effect of cilostazol on increasing peripheral blood flow in arteriosclerosis obliterans.
    Yasuda K, Sakuma M, Tanabe T.
    Arzneimittelforschung; 1985; 35(7A):1198-200. PubMed ID: 4074434
    [Abstract] [Full Text] [Related]

  • 3. Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion.
    Ohashi S, Iwatani M, Hyakuna Y, Morioka Y.
    Arzneimittelforschung; 1985; 35(7A):1203-8. PubMed ID: 4074436
    [Abstract] [Full Text] [Related]

  • 4. General pharmacological properties of cilostazol, a new antithrombotic drug. Part II: Effect on the peripheral organs.
    Shintani S, Watanabe K, Kawamura K, Mori T, Tani T, Toba Y, Sasabe H, Nakagiri N, Hongoh O, Fujita S.
    Arzneimittelforschung; 1985; 35(7A):1163-72. PubMed ID: 3000392
    [Abstract] [Full Text] [Related]

  • 5. Long-term effect of cilostazol on cerebral blood flow in chronic cerebral infarction.
    Kobayashi S, Yamaguchi S, Katsube T, Kitani M, Okada K, Tsunematsu T.
    Arzneimittelforschung; 1985; 35(7A):1193-7. PubMed ID: 4074433
    [Abstract] [Full Text] [Related]

  • 6. Effect of cilostazol, a new antithrombotic drug, on cerebral circulation.
    Kawamura K, Watanabe K, Kimura Y.
    Arzneimittelforschung; 1985; 35(7A):1149-54. PubMed ID: 4074427
    [Abstract] [Full Text] [Related]

  • 7. Effect of cilostazol, a new antithrombotic drug, on an experimental model of peripheral circulation insufficiency.
    Kawamura K, Fujita S, Tani T, Kimura Y.
    Arzneimittelforschung; 1985; 35(7A):1154-6. PubMed ID: 4074428
    [Abstract] [Full Text] [Related]

  • 8. Clinical effects of oral cilostazol on suppression of platelet function in patients with cerebrovascular disease.
    Yasunaga K, Mase K.
    Arzneimittelforschung; 1985; 35(7A):1186-8. PubMed ID: 4074431
    [Abstract] [Full Text] [Related]

  • 9. Antiaggregatory effect of oral cilostazol and recovery of platelet aggregability in patients with cerebrovascular disease.
    Yasunaga K, Mase K.
    Arzneimittelforschung; 1985; 35(7A):1189-92. PubMed ID: 4074432
    [Abstract] [Full Text] [Related]

  • 10. Effect of cilostazol on platelet aggregation and experimental thrombosis.
    Kimura Y, Tani T, Kanbe T, Watanabe K.
    Arzneimittelforschung; 1985; 35(7A):1144-9. PubMed ID: 4074426
    [Abstract] [Full Text] [Related]

  • 11. Hemodynamic effects of cilostazol on peripheral artery in patients with diabetic neuropathy.
    Okuda Y, Mizutani M, Ikegami T, Ueno E, Yamashita K.
    Arzneimittelforschung; 1992 Apr; 42(4):540-2. PubMed ID: 1642679
    [Abstract] [Full Text] [Related]

  • 12. General pharmacological properties of cilostazol, a new antithrombotic drug. Part I: Effects on the central nervous system.
    Shintani S, Toba Y, Suzuki S, Ninomiya S, Umezato M, Hiyama T.
    Arzneimittelforschung; 1985 Apr; 35(7A):1157-62. PubMed ID: 4074429
    [Abstract] [Full Text] [Related]

  • 13. Physico-chemical properties and stability of cilostazol.
    Shimizu T, Osumi T, Niimi K, Nakagawa K.
    Arzneimittelforschung; 1985 Apr; 35(7A):1117-23. PubMed ID: 4074422
    [Abstract] [Full Text] [Related]

  • 14. The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man.
    Akiyama H, Kudo S, Shimizu T.
    Arzneimittelforschung; 1985 Apr; 35(7A):1133-40. PubMed ID: 4074424
    [Abstract] [Full Text] [Related]

  • 15. The localization of a new antithrombotic agent, cilostazol, in CHO-K1 cells as demonstrated by autoradiography.
    Usuda N, Nagata T, Naka M, Hidaka H.
    Arzneimittelforschung; 1985 Apr; 35(7A):1141-3. PubMed ID: 4074425
    [Abstract] [Full Text] [Related]

  • 16. Increased external carotid artery blood flow in headache patients induced by cilostazol. Preliminary communication.
    Yamashita K, Kobayashi S, Okada K, Tsunematsu T.
    Arzneimittelforschung; 1990 May; 40(5):587-8. PubMed ID: 2383301
    [Abstract] [Full Text] [Related]

  • 17. The absorption, distribution and excretion of a new antithrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog and man.
    Akiyama H, Kudo S, Shimizu T.
    Arzneimittelforschung; 1985 May; 35(7A):1124-32. PubMed ID: 4074423
    [Abstract] [Full Text] [Related]

  • 18. Phase I study of cilostazol. Safety evaluation at increasing single doses in healthy volunteers.
    Niki T, Mori H.
    Arzneimittelforschung; 1985 May; 35(7A):1173-85. PubMed ID: 4074430
    [Abstract] [Full Text] [Related]

  • 19. Cilostazol increases skin perfusion pressure in severely ischemic limbs.
    Miyashita Y, Saito S, Miyamoto A, Iida O, Nanto S.
    Angiology; 2011 Jan; 62(1):15-7. PubMed ID: 20504836
    [Abstract] [Full Text] [Related]

  • 20. The pharmacology of cilostazol.
    Schrör K.
    Diabetes Obes Metab; 2002 Mar; 4 Suppl 2():S14-9. PubMed ID: 12180353
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.